OligoHA Modulation of Dendritic Cell Activity for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD) and skin inflammation are inadequate in controlling disease severity and maintaining quality of life, and the interplay between bacterial and host hyaluronan systems in infection and inflammation remains poorly understood.
Innovation Solution
The use of oligoHA, specifically tetrasaccharides, to suppress contact hypersensitivity reactions and modulate dendritic cell function through topical creams or subcutaneous injections, and the application of hyaluronidase to inhibit bacterial infection by reducing hyaluronan degradation, thereby influencing bacterial translocation and adipogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting inflammatory cytokines and receptors are used for IBD, then some inflammatory symptoms are addressed, but disease severity control and quality of life maintenance remain insufficient
Solution Approach 1:
The patent introduces oligoHA as a mediator substance that modulates the immune response in IBD. OligoHA acts as an intermediary between the inflammatory cytokines and the immune cells, specifically targeting dendritic cells to reduce their activation and migration, thereby providing a new therapeutic mechanism that complements existing cytokine-targeting therapies
Solution Approach 2:
The patent changes the therapeutic parameter from directly blocking cytokines to modulating hyaluronan metabolism. By administering oligoHA or hyaluronidase, the patent alters the biochemical environment in the gut, changing the physical and chemical parameters of the extracellular matrix to influence immune cell behavior and reduce inflammation
2Object-affected harmful factors
If hyaluronidase is used to degrade hyaluronan during bacterial infection, then bacterial translocation may be reduced, but excessive degradation can compromise tissue structure and function
Solution Approach 1:
The patent applies partial degradation of hyaluronan rather than complete degradation. By using hyaluronidase to partially break down hyaluronan into oligoHA fragments, the patent achieves enough degradation to reduce bacterial translocation while maintaining sufficient hyaluronan remaining to preserve tissue structural integrity
Solution Approach 2:
The patent changes the molecular weight parameter of hyaluronan from high molecular weight (structural form) to low molecular weight oligoHA fragments (functional form). This parameter change allows the same substance to transition from providing structural support to modulating immune response and reducing bacterial translocation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
OligoHA treatment effectively suppresses allergic reactions and inflammation by reducing dendritic cell activity and bacterial translocation, improving sensitization and reducing infection risk, while hyaluronidase application decreases adipogenesis and inflammation in both skin and gastrointestinal tract.
Implementation Method 1
OligoHA treatment effectively suppresses allergic reactions and inflammation by reducing dendritic cell activity
Implementation Method 2
the application of hyaluronidase to inhibit bacterial infection by reducing hyaluronan degradation
Implementation Method 3
hyaluronidase application decreases adipogenesis and inflammation in both skin and gastrointestinal tract
Data Source
AI summary
The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.